SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced ...

SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced ...

Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

In order to see if the company can achieve success in targeting patients with 2nd-line EGFR-mutant locally advanced or metastatic non-squamous non-small cell lung cancer [NSCLC] using ivonescimab ...

The article " Regeneron: Is It the Perfect Biotech Stock for Value and Growth? " first appeared on MarketBeat.

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

In 2024, we began a phase two clinical trial of FID-007 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. So far, we have dosed ...